

Competitor Analysis: Cancer Antibodies in Early Clinical Development

<https://marketpublishers.com/r/CF9AB2CB718EN.html>

Date: February 2011

Pages: 183

Price: US\$ 1,210.00 (Single User License)

ID: CF9AB2CB718EN

Abstracts

Product description

The present Competitive Intelligence Report about Cancer Antibodies in Early Clinical Development provides a competitor evaluation in the field of antibody therapeutics being developed for treatment of solid and hematologic malignancies as of February 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Marketed therapeutic antibodies for treatment of cancer achieved combined sales of over US\$ 18 bln in the year 2009. Among them are the blockbuster antibodies Avastin, Rituxan/MabThera and Herceptin. The development pipeline of novel cancer antibodies in early clinical phases is full, not only of antibodies against the validated targets CD20, VEGF and Her2, but also of many new and unique antibodies directed against novel targets which will have to show its clinical validity. The technology of antibody-drug conjugates is gaining popularity as evidenced by an ever growing pipeline.

The report includes a compilation of currently active projects in early clinical research and development of antibody therapeutic for treatment of cancer. In addition, the report lists company-specific R&D pipelines of anti-cancer antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

Index

Antibody Drug Conjugates (ADC)

Immunotoxins

Immunocytokines

CD19

CD20

CD22

CD30

CD40

IGF-1/R

PDGF-R

EGF-R

Her2

VEGF-R

FGF-(R)

TGF-(R)

CEA

EpCAM

PSA & PSMA

c-Met/HGF

TRAIL-R1/2

B7 – CD28/CLTA4 Pathway

Delta-like ligand 4 (DLL4) inhibitor (DLL4 = vascular-specific notch ligand)

IL-6

Angiopoietin

CCR2 chemokine receptor

ErbB3 / Her3

CD38

Unique Antibodies

Corporate Early Clinical Stage Cancer Antibody R&D Pipelines

Abbott

Active Biotech

Affirmed Therapeutics

Albert Einstein College of Medicine

Alder Biopharmaceuticals

Alexion Pharmaceuticals

Altor Biosciences

Amgen

Angimmune

Apeiron Biologics

Apogenix

Astellas Pharma

AstraZeneca

AVEO Pharmaceutical

Bayer Schering Pharma

Biocon

Biogen Idec

BioInvent

Biotest

BioWa

Boehringer Ingelheim Pharmaceuticals

Bristol-Myers Squibb (BMS)

BZL Biologics

Celldex Therapeutics

Celltrion

Centocor (J&J)

CureTech

Daiichi-Sankyo

Debiopharm

Dong-A Pharmaceutical

Eisai

Eli Lilly

Emergent Biosolutions

Fibrogen

Five Prime Therapeutics

Fresenius Biotech

Ganymed Pharmaceuticals

Genmab

Genzyme

GlaxoSmithKline

Glycotope

Helix BioPharma

Hokkaido UniversityHospira

Human Genome Sciences

ImaginAb

ImmunogenImmunomedics

Innate Pharma

Kissei Pharmaceutical

Kyowa Hakko Kirin Pharma

LFB Biotechnologies

Life Science Pharmaceuticals

Lpath

Ludwig Institute for Cancer Research (LICR)

MAbgen

MacroGenics

MAT Biopharma

MD Anderson Cancer Center

Memorial Sloan Kettering

Mentrik Biotech

Merck & Co

Merck Serono

Merrimack Pharmaceuticals

Micromet

MorphoSys

National Cancer Institute (NCI)

Neogenix Oncology

Novartis

Ono

OncoMed Pharmaceuticals

Oncoscience

Pain Therapeutics

PanGenetics

Patrys

Peregrine Pharmaceutical

Pfizer

Philogen

Progenics

Provenance Biopharmaceuticals

Quest PharmaTech

Radboud University

Recepta Biopharma

Regeneron Pharmaceuticals

Roche (Genentech)

Sanofi-Aventis

Seattle Genetics

Scott & White Hospital and Clinic

Simmons Cancer Center

Spectrum Pharmaceuticals

Symphogen

Takeda

Targa Therapeutics

TenX Biopharma

Teva Pharmaceutical Industries

ThromboGenics

TopoTarget

TRACON Pharmaceutical

TRION Pharma

United Therapeutics

UCB

Vaccinex

Viventia Biotech

Weill Medical College

Wilex

XBiotech

Xencor

XOMA

YM Biosciences

Zenotech

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

I would like to order

Product name: Competitor Analysis: Cancer Antibodies in Early Clinical Development

Product link: <https://marketpublishers.com/r/CF9AB2CB718EN.html>

Price: US\$ 1,210.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF9AB2CB718EN.html>